Targeted Oncology· @TargetedOnc · X·· 14 小时前评分70
正文 · 原文
Remarkable OS benefit in ES-SCLC! #ESMO26
DeLLphi-305: Tarlatamab + durvalumab maintenance vs durvalumab:
Median OS: 21.1 vs 12.7 mo (HR 0.42)
PFS: 7.4 vs 1.9 mo (HR 0.34)
An 8.4-month difference in median survival. Potentially practice-changing!
73 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Targeted Oncology · x.com